ABVX ABIVAX Société Anonyme
ABIVAX Société Anonyme (ABVX) is confirmed to report earnings on September 21, 2026, after the market close. The consensus earnings estimate is a loss of $1.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.1% since its last earnings release on May 22, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About ABIVAX Société Anonyme
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases
Sector
Healthcare
Industry
Biotechnology